The work is focused on anticancer properties of dipicolinate
(dipic)-based
vanadium(IV) complexes [VO(dipic)(N∩N)] bearing
different diimines (2-(1H-imidazol-2-yl)pyridine,
2-(2-pyridyl)benzimidazole, 1,10-phenanthroline-5,6-dione, 1,10-phenanthroline,
and 2,2′-bipyridine), as well as differently 4,7-substituted
1,10-phenanthrolines. The antiproliferative effect of V(IV) systems
was analyzed in different tumors (A2780, HCT116, and HCT116-DoxR)
and normal (primary human dermal fibroblasts) cell lines, revealing
a high cytotoxic effect of [VO(dipic)(N∩N)] with
4,7-dimethoxy-phen (5), 4,7-diphenyl-phen (6), and 1,10-phenanthroline (8) against HCT116-DoxR cells.
The cytotoxicity differences between these complexes can be correlated
with their different internalization by HCT116-DoxR cells. Worthy
of note, these three complexes were found to (i) induce cell death
through apoptosis and autophagy pathways, namely, through ROS production;
(ii) not to be cytostatic; (iii) to interact with the BSA protein;
(iv) do not promote tumor cell migration or a pro-angiogenic capability;
(v) show a slight in vivo anti-angiogenic capability,
and (vi) do not show in vivo toxicity in a chicken
embryo.